Development of novel nucleic acid drugs for chronic hepatitis C virus infection
| Project/Area Number |
25860280
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Tokyo Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | ドラッグデリバリー / HCV / エクソソーム / 慢性Ｃ型肝炎 |
|---|
| Outline of Final Research Achievements |
In order to achieve the treatment of chronic hepatitis C with a nucleic acid, the present study aimed at new development of nucleic acid drugs and DDS for the purpose of treatment of fibrosis and rejection of HCV. To establish a modified exosomes producing cell, the envelope expression vector of HCV and to prepare a packaging vector. Modified exosomes that were established in this study, it is possible that the beginning can be widely used for the treatment of chronic hepatitis C as a DDS for delivering efficient pharmaceutical into hepatocytes. Also packaging system enclosing the efficient nucleic acid medicine to a modified exosomes are expected to promote the realization of the nucleic acid drugs.
|
Report
(3 results)
Research Products
(9 results)
